AnaptysBio, Inc.
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-3…
Biotechnology
US, San Diego [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about AnaptysBio, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2016 | - | -0.127 | - | 16 | - | -3 | - | -13 | - | -13 | - | 27 |
| 2017 | -0.2300 | -1.655 | 16 | 7 | -4 | -44 | -3 | -6 | -18 | -6 | 4 | 13 |
| 2018 | -1.5200 | -2.854 | 10 | 4 | -30 | -64 | -28 | -68 | -58 | -70 | 9 | 7 |
| 2019 | -2.5000 | -4.052 | 5 | 7 | -61 | -109 | -59 | -5 | -122 | -5 | 15 | 12 |
| 2020 | -3.6000 | 0.043 | 8 | 95 | -97 | -12 | -95 | -13 | -206 | -16 | 16 | 19 |
| 2021 | -0.7300 | -1.833 | 75 | 63 | -19 | -49 | -19 | -52 | -103 | -52 | 18 | 108 |
| 2022 | -2.0800 | -4.526 | 63 | 9 | -57 | -26 | -55 | -16 | -155 | -19 | 21 | 15 |
| 2023 | -4.5700 | -6.069 | 10 | 11 | -128 | -163 | -105 | -15 | -117 | -18 | 36 | 20 |
| 2024 | -6.0800 | -6.084 | 17 | 55 | -163 | -165 | -143 | -46 | -166 | -46 | 41 | 96 |
| 2025 | - | -5.364 | - | 35 | - | -184 | - | -29 | - | -29 | - | 61 |
| 2026 | - | 2.F10X/td> | - | 2.F10X/td> | - | 2.F10X/td> | - | 2.F101/td> | - | 2.F101 | - | 2.F101 |
| 2027 | - | 1.F11X/td> | - | 1.F11X/td> | - | 1.F11X/td> | - | 1.F111/td> | - | 1.F111 | - | 1.F111 |
| 2028 | - | 0.F12X/td> | - | 0.F12X/td> | - | 0.F12X/td> | - | 0.F121/td> | - | 0.F121 | - | 0.F121 |